Post-vitrectomy tissue plasminogen activator injection for central retinal vein occlusion.
Three patients with recent central retinal vein occlusion underwent vitrectomy, fluid-air exchange, and a 50-microg tissue plasminogen activator intravitreal injection. After a mean follow-up period of 38.7 weeks, no patient's vision improved and one patient required an additional vitrectomy. Post-vitrectomy tissue plasminogen activator injection did not improve the course of central retinal vein occlusion in these three cases.
Christodoulakis
Emmanouil V
EV
Retina Service, Ophthalmology Clinic, Heraklion University Hospital, Crete, Greece.
Tsilimbaris
Miltiades K
MK
D000368:Aged; D000369:Aged, 80 and over; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008297:Male; D011182:Postoperative Care; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000628:therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome; D014792:Visual Acuity; D014821:Vitrectomy
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator